WO2002100431A1 - Kit pharmaceutique comprenant une proteine de fusion carboxypeptidase humaine dirigee contre un anticorps a chaine simple de proteine plasmatique seminale et promedicament - Google Patents
Kit pharmaceutique comprenant une proteine de fusion carboxypeptidase humaine dirigee contre un anticorps a chaine simple de proteine plasmatique seminale et promedicament Download PDFInfo
- Publication number
- WO2002100431A1 WO2002100431A1 PCT/CN2001/000924 CN0100924W WO02100431A1 WO 2002100431 A1 WO2002100431 A1 WO 2002100431A1 CN 0100924 W CN0100924 W CN 0100924W WO 02100431 A1 WO02100431 A1 WO 02100431A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- human
- fusion protein
- carboxypeptidase
- chain antibody
- prodrug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to the field of antibody-directed enzyme-prodrug therapy (ADEPT). More specifically, the present invention relates to an anti-human seminal plasma single chain antibody / human carboxypeptidase A fusion protein and a prodrug methotrexate- OC-peptide derivative kit, which is suitable for treating prostate cancer by ADEPT therapy. The invention also relates to an anti-human seminal plasma single chain antibody / human carboxypeptidase A fusion protein.
- ADEPT antibody-directed enzyme-prodrug therapy
- chemotherapeutic drugs lack high selectivity to tumor tissues, and often have toxic and side effects on the normal tissues of the body while acting on tumor tissues.
- the proposal of monoclonal antibodies provides a basis for tumor-directed therapy. It is hoped that monoclonal antibodies can specifically bring toxic drugs directly to tumor tissue sites, but in practice, it is found that toxic drugs cannot reach tumor sites very effectively. This is because : (1) an antibody can only carry a certain number of drugs, (2) the amount of antigens in tumor tissues varies, (3) large antibody-drug cross-linkers are difficult to reach the substantial tumor site, and (4) it is easy to cause immunity reaction.
- ADPT antibody-directed enzyme-prodrug therapy
- mol carboxypeptidase G2 can degrade 800 mol benzoic acid nitrogen mustard substrate in one second, and produce a high concentration of active drug at the tumor site, which can make up for the shortcoming of the low binding power of immunoconjugates in clinical applications. There is also evidence that It is more effective to produce high concentrations of drugs on the surface of tumor cells than to apply the same concentration of active drugs throughout the body.
- Methotrexate is an anti-metabolic tumor chemotherapy drug, which is widely used, but MTX not only kills tumor cells, but also inhibits normal cells, causing severe toxic reactions and limiting clinical high Concentration and large-dose use affect the treatment effect. If any ⁇ -amino acid is connected to the ⁇ -carboxyl group of carboxyl-terminal glutamic acid of MTX, it becomes an MTX- ⁇ -peptide. This compound is not toxic to all cells. When it encounters a suitable carboxypeptidase to hydrolyze carboxypeptide bonds, it can release cytotoxic MTX, which is an antibody-directed enzyme-prodrug therapy ( ADEPT) provides favorable conditions.
- ADEPT antibody-directed enzyme-prodrug therapy
- ADEPT Since the concept of ADEPT was proposed by Bagshawe in 1987, it has developed rapidly, and part of it has entered the phase I clinical experiment. However, the heterogeneity of mouse-derived monoclonal antibodies and activating enzymes is the biggest obstacle that limits the in vivo application of ADEPT therapy. Cross-linking of antibody / human-derived activating enzyme is the development direction of ADEPT. Genetic engineering of single-chain antibodies in place of murine monoclonal antibodies should solve the problem of antibody heterogeneity. This is because the genetically engineered single-chain antibody retains only the variable region of the antibody with specific antigen binding, and removes the constant region of the antibody, which differs greatly in species. It is only 1/6 of the intact antibody and has good affinity and stability.
- the fusion protein constructed by genetically engineered single-chain antibody and activating enzyme gene can both specifically bind tumor cells and hydrolyze prodrugs, and avoid enzyme inactivation and antibody inactivation during chemical coupling.
- its biggest advantage is that it is easy to prepare in large quantities, which is convenient for future clinical use.
- ⁇ -Seminoprotein is a prostate-specific antigen secreted by prostate epithelial cells in semen, with a molecular weight of 23,000-33,000. It was used for forensic identification in the early years. In recent years, people have used anti- ⁇ -Sm Serum was localized by histochemical staining and found to be found in prostate cancer cells and metastatic cells (hara Saburo, ⁇ -Seminoprotein ⁇ !: (i 'Hoichio immunochemical traits. Clinicopathology, 1986; Special (68): 50), while it is not found in other human tissues and malignancies. It is currently associated with prostate specific antigen (prostatic specific antigen, PSA) -likely recognized as a specific marker for prostate cancer.
- PSA prostate specific antigen
- Carboxypeptidase A is a carboxypeptidase secreted by a portion of mammalian tissues, with a gene length of 1251 bp and a total of 417 amino acids. It can hydrolyze aliphatic and aromatic amino acids in sequence from the C-terminus of the polypeptide chain. Using this property, carboxypeptidase A was first applied to ADEPT therapy research.
- the inventors proceeded from the self-constructed anti-human seminal plasma single chain antibody, combined with human carboxypeptidase and the prodrug methotrexate- ⁇ -peptide derivative, and conducted in-depth research on the treatment of prostate cancer, thus completing This invention.
- an object of the present invention is to provide a kit for treating prostate cancer via antibody-directed enzyme-prodrug therapy.
- the kit includes an anti-human seminal plasma single chain antibody / human carboxypeptidase A fusion protein and a precursor. Drug methotrexate- ⁇ -peptide derivative.
- Another object of the present invention is to provide an anti-human seminal plasma single chain antibody / human carboxypeptidase A fusion protein and a polynucleotide encoding the same.
- the present invention provides a kit for treating prostate cancer via antibody-directed enzyme-prodrug therapy.
- the kit includes a plurality of containers, each containing an anti-human seminal plasma single-chain antibody / human carboxylate.
- Peptidase A fusion protein, prodrug methotrexate- ⁇ -peptide derivative, and pharmacologically acceptable auxiliary agent for administration wherein the anti-human seminal plasma single chain antibody / The human carboxypeptidase A fusion protein was administered at least 72 hours before the prodrug administration.
- the prodrug is methotrexate-alpha-phenylalanine.
- the sequence of the anti-human seminal plasma single chain antibody / human carboxypeptidase A fusion protein is shown in FIG. 4.
- Another aspect of the present invention provides an anti-human seminal plasma single-chain antibody / human carboxypeptidase A fusion protein and a polynucleotide encoding the same, wherein the amino acid sequence of the fusion protein is shown in FIG. 4. The sequence is shown in Figure 3.
- first seminoprotein E4B7 from the anti-human hybridoma cell lines (the present invention to save) starting anti-human seminal plasma protein construct single chain antibody, and by RT _ PGR Methods
- the human carboxypeptidase A gene was amplified from human lung tissue. Based on this, an anti-human seminal plasma single chain antibody / human carboxypeptidase A fusion gene was constructed by using end-PCR and overlapping extension splicing method. See the description of the examples.
- the inventors designed the single-chain anti-human seminal plasma protein by computer design.
- a linker of 6 amino acid sequences was added between the antibody and the sequence of the human carboxypeptidase A coding region, and the fusion protein of the present invention was constructed by the overlapping extension splicing method.
- this method does not require the use of restriction enzymes and ligases, can avoid the introduction of nucleotide sequences of restriction sites, and can accurately link two gene fragments together. Is a fast and effective means of constructing fusion genes.
- the biological activity of the expressed fusion protein showed that it had human seminal plasma protein single chain antibody and human carboxypeptidase A activity ( Figure 5 and Figure 6).
- the experiment of the kit of the present invention shows that the kit of the present invention has a significant effect on treating prostate cancer.
- the fusion protein in the kit of the present invention is administered at least 72 hours before the administration of the prodrug.
- the dosage and route of administration can be easily determined experimentally by those skilled in the art or clinicians according to the symptoms of the patient.
- Figure 1 shows the construction strategy of the anti-human seminal plasma single chain antibody / human carboxypeptidase A fusion gene of the present invention.
- Fig. 2 is an agarose gel electrophoresis photograph showing the results of the fusion gene construction of the present invention.
- Figure 3 is the nucleotide sequence of the fusion gene of the present invention.
- Figure 4 shows the amino acid sequence of the fusion protein of the present invention.
- Figure 5 shows the expression of the fusion protein of the present invention.
- Figure 6 shows the activity of the fusion protein of the present invention in binding to prostate cancer cell lines.
- FIG. 8 is a killing curve of a prodrug on prostate cancer cells, and the experiment is as described in Example 2.
- FIG. 9 shows the effect of different drug treatment groups on the cell cycle of prostate cancer cells. The experiment is as described in Example 2.
- Fig. 10 shows the tumor growth curves of different treatment groups. The experiment is as described in Example 2.
- FIG. 11 shows a control map of tumor growth in nude mice of the ADEPT treatment group and the control group. The experiment is as described in Example 2.
- an anti-human seminal plasma single-chain antibody / human carboxypeptidase A fusion gene Construction and expression of an anti-human seminal plasma single-chain antibody / human carboxypeptidase A fusion gene.
- an anti-human seminavidin single-chain antibody was constructed and expanded it from 'human lung tissue' by RT-PCR.
- an anti-human sphingoprotein / carboxypeptidase A fusion gene was constructed using end-PCR and overlapping extension splicing method, and the fusion gene was subjected to prokaryotic expression and activity determination.
- the anti-human seminal plasma protein hybridoma cell line E 4 B 7 was prepared by the present inventors, and the cell secreted an anti-human seminal plasma protein monoclonal antibody ( Y- Sm-McAb).
- E. coli JM109 and pUC19 plasmids were preserved by the inventors; restriction enzymes, TaqDNA polymerase, reverse transcription kit (Reverse Transcription System), plasmid extraction purification kit (Wizard TM Plus Minipreps DNA Purification System) GST fusion protein
- the expression vector pGEX-4T-l is a product of Promega; the Rapid Ligation Kit was purchased from Boeringer Mannheim; the Advantage TM PCR-Pure Kit was a product of Clontech; IPTG (isopropyl- ⁇ -D-thioxo Galactoside) was purchased from Huamei Company. The remaining reagents are Sigma products.
- Total cell RA extraction and reverse transcription Total RNA extraction was performed by conventional methods. Total RNA extracted from 2 X 10 7 anti-human seminal plasma protein hybridoma cell lines E 4 B 7 cells was dissolved in 30 ⁇ 1 RNase-free water, and 5 ⁇ 1 was taken according to the Reverse Transcriptian System (Promega, USA) Instructions for reverse transcription.
- the Linker sequence is a 15-peptide sequence (Giy 4 Ser) 3 that Huston analyzes the structure of the variable region of an antibody based on X-ray crystal diffraction. Design two primers based on the Linker sequence:
- V n V H gene in the PCR product was cloned into the pUC19 -Linker plasmid in order to construct an E 4 B 7 single chain antibody. After transformation, positive colonies containing single-chain antibody genes were extracted from the recombinant plasmids and sequenced.
- PA primer design and synthesis Search the entire gene sequence of Genbank human carboxypeptidase A, and design a pair of primers on both sides of the mature protein coding region. The synthesis of the primers was completed by Beijing Saibaisheng (USA) Bioengineering Co., Ltd. as follows:
- the PCR reaction conditions were: denaturation at 94 ° C for 1 min, annealing at 50 ° C for 1.5 min, extension at 72 ° C for 2 min, after 30 cycles, and extension at 72 ° C for 10 min.
- the PCR product was subjected to 15g / L agarose gel electrophoresis to identify the effect of amplification.
- Human carboxypeptidase A For: 3 'primer for amplifying the human carboxypeptidase A gene;
- a fusion protein Take 100ml of induced expression bacterial solution, and perform preliminary purification, denaturation and renaturation according to conventional methods, and then use GST The affinity chromatography column was further purified and lyophilized after digestion with thrombin. The antibody binding activity was measured using a competitive cytometry inhibition test using a flow cytometer. The fusion protein was added to a culture medium containing 1 ⁇ 10 6 prostate cancer cells for 45 minutes, and then the parent antibody (anti-human seminal plasma monoclonal antibody) was added.
- VH Back V H For and V L Back, V L For primers designed for the 5 'end and 3' J region conserved sequences of murine antibody heavy and light chain variable region genes were amplified from B 4 B 7 McAb
- E 4 B 7 V H and V L genes were digested and identified by EcoR 1 and Hindlll, and DNA fragments of about 360bp and 330bp were obtained, respectively. Consistent with the expected murine antibody variable region gene size.
- the nucleotide sequence of E 4 B 7 V H and V L was determined by a full-automatic fluorescent sequence analyzer. As a result, the V H gene was an open reading frame, consisting of 358 bp, encoding 119 amino acids, and the amino acids at positions 22 and 95 were antibodies.
- the ligated product of E 4 B 7 V H and VL genes was identified by PCR amplification, and an insert of about 750 bp in size was visible.
- the E 4 B 7 single-chain antibody was sequenced using a full-automatic fluorescent DNA sequencer, and the sequences of V H , VL and Linker were all correct.
- the anti-human seminal plasma single-chain antibody gene and human carboxypeptidase A gene were respectively subjected to a terminal PCR reaction, and complementarity was introduced at the 3, terminal of the anti-human seminal plasma protein single-chain antibody gene and the 5, terminal of the human carboxypeptidase A gene. Nucleotide sequence. Then, the two PCR products mentioned above were mixed, and the two were ligated into an anti-human seminal plasma single chain antibody / human carboxypeptidase A fusion gene by SOE reaction. After 15g / L agarose gel electrophoresis analysis, the full length of the anti-human seminal plasma antibody / human carboxypeptidase A fusion gene was about 1980 bp ( Figure 2).
- the induced GST-single-chain antibody / human carboxypeptidase A fusion protein was subjected to SDS-polyacrylamide gel electrophoresis, and a nascent protein band of about 94,000 Mr was seen (Figure 5).
- the expression level measured by thin-layer scanner accounted for about 34% of the total bacterial protein.
- the fusion protein is in the form of an inclusion body. Purified by conventional denaturation, renaturation, and affinity chromatography, purified single chain antibody / human carboxypeptidase A fusion protein can be obtained. The sequencing results of the fusion protein are shown in Figure 4.
- Methotrexate is a product of Shanghai Twelfth Pharmaceutical Factory.
- Methotrexine- ⁇ -peptide derivative Methotrexate- ⁇ -phenylalanine (MTX- ⁇ - Phe) and methotrexate-a-arginine (MTX-a-Arg) were synthesized by the inventors, and were determined to be a single peak by high performance liquid chromatography. The molecular weight determined by laser mass spectrometry was consistent with the theoretical value.
- -A carboxypeptidase Products as Si g ma.
- Anti-human seminal protein monoclonal antibody-carboxypeptidase A conjugate-SmMcAb-CP-A) was prepared by the present inventors according to the thioether method (Melton R'G. LImmunoL Methods, 1993, 158: 49), anti-human sperm A plasma protein single chain antibody / human carboxypeptidase A fusion protein was prepared as in Example 1 .
- the CP-A enzyme activity of the conjugate was 20 U / mg (CP-A: McAb).
- the biological activity of the fusion protein showed that it had human seminal plasma protein single chain antibody and human carboxypeptidase A activity (see Examples).
- Tumor model 4-6 week old BALB / C nude mice (provided by Animal Center, Fourth Military Medical University), weight
- MTT test PC-3, PC-3m cells were added to 96-well culture plate, each well 1 ⁇ 104 C ell / ml, while adding various concentrations of MTX, MTX- a _Phe, MTX- a -Phe + CP- A, MTX- a -Phe + fusion protein and MTX- a -Arg, MTX- a -Arg + fusion protein, each concentration was set in 3 parallel wells, and incubated in a 37 ′ C CO 2 incubator for 48 h.
- Colony formation test Divided into 9 groups by soft agar culture method: 1 MTX + tumor cells; 2 MTX- a -Phe + tumor cells; 3 fusion protein + tumor cells; 4 MTX- a -Phe + CP-A + Tumor cells; 5 MTX-a-Phe + fusion protein + tumor cells; 6 MTX- ⁇ -Arg + tumor cells; 7 MTX- a -Arg + CP-A + tumor cells; 8 MTX- a -Arg + fusion protein + tumor cells 9 Control group (tumor cells).
- test drugs MTX, MTX-a-Phe, MTX-a-Arg are divided into three concentrations (0.4, 4, 40ug / ml), CP-AlOul (2.5mU / ul), and fusion protein 10ul (lmg / ml) ), 200 tumor cells / well. Incubate at 37 ° C, 50ml / L C0 2 for 2wk, fix with acetic acid and ethanol mixed solution (1: 3) for 2h, and calculate the colony formation rate under the microscope.
- Grouping and treatment 56 tumor-bearing nude mice were randomly divided into groups according to tumor size: 1 control group, 0.5ml saline, intravenous administration; 2 treatment group I, MTX 5mg / kg, intravenous administration; 3 treatment Group II, MTX-a-Phe5.32mg / kg, intravenously administered; 4 Treatment group III, seminal plasma monoclonal antibody-carboxypeptidase A conjugate (Y-SmMcAb-CP-A) 0.5ml, intravenously administered 5 In the treatment group IV, 0.5ml of fusion protein was administered intravenously; 6 In the treatment group V, 0.5ml of the conjugate was administered intravenously, and MTX-a-Phe5.32mg / kg (ADEPT-1) was administered intravenously 72 hours later. 7 In treatment group VI, 0.5 ml of fusion protein was administered intravenously, and MTX-a-Phe 5.32 mg / kg (ADEPT-2) was administered intravenously 72
- Fusion protein was labeled with 125 1 and ECT imaging was performed at 12h, 24h, 48h, 72h, and 96h after intravenous injection, and the localization of the antibody was observed.
- Two nude mice were killed and swollen. Tumor, brain, heart, liver, spleen, lung, kidney, stomach, small intestine, mesentery lymph node, skeletal muscle, ovary, testis, one part is directly measured for radioactivity in blood and various organs after weighing.
- Tissue homogenate take a certain amount of tissue homogenate, add an equal amount of 200ml / L trichloroacetic acid to precipitate, measure the radioactivity of the precipitated part, and calculate the content of fusion protein in the tissue.
- Tumor cell growth cycle time [lg (1 + G) / lg] ⁇
- G is the tumor growth component
- mm x is the tumor mass at different observation times in a component
- t is the observation interval time.
- Nude mouse survival time refers to the time from treatment to natural death.
- MTX, MTX- ⁇ - Phe + CP-A, MTX- ⁇ - Phe + fusion proteins have a strong inhibitory effect, and no colony formation (P ⁇ 0 ⁇ ⁇ ) ; the fusion protein has a certain effect on the growth of prostate cancer cells Inhibition effect, colony formation rate was 68% , which was different from the control group (? ⁇ 1 ).
- Distribution of fusion protein in the body The distribution of markers in blood, tumor and various organs is shown in Table ECT at 12h , 24h , 48h , 72h and 96h after injection of 125 1 marker. Aggregation was best at 72 h with a T / NT value of 12.65. It shows that the antibody can carry the fusion protein and locate at the tumor site very well.
- tumor cell cycle time comparing survival time of nude mice: each group of nude mouse tumor cell growth and survival cycle time, rapid tumor growth in the control group, the cell cycle time of a 0 ⁇ 1 ⁇ 5 persons 3 of them had extensive metastasis of the abdominal cavity, severe ascites, severe malignant heterogeneity, and an average survival of 28 ⁇ 11.7 days. There was no significant change in ⁇ , III, IV between the treatment group and the control group (P ⁇ 0.05), and the cell growth cycle time was 1 ⁇ 7 ⁇ 0.2, 2 ⁇ 7 ⁇ 0 ⁇ 2, and 1 ⁇ 9 ⁇ 0 ⁇ 1, and the average survival times were respectively It was 31 ⁇ 12.2 days, 39 ⁇ 15 ⁇ 8 days, and 34 ⁇ 14.1 days.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2001/000924 WO2002100431A1 (fr) | 2001-06-08 | 2001-06-08 | Kit pharmaceutique comprenant une proteine de fusion carboxypeptidase humaine dirigee contre un anticorps a chaine simple de proteine plasmatique seminale et promedicament |
US10/479,888 US20050053611A1 (en) | 2001-06-08 | 2001-06-08 | Pharmaceutical kit comprising anti-human seminal plasma protein single chain antibody/human carboxypeptidase fusion protein and prodrug |
EP01969178A EP1459761A4 (en) | 2001-06-08 | 2001-06-08 | PHARMACEUTICAL SET WITH ANTI-HUMAN SPERM PLASMAPROTEIN SINGLE CHAIN ANTIBODY / HUMAN CARBOXYPEPTIDASE FUSION PROTEIN AND PRODRUG |
CNB018233376A CN1278739C (zh) | 2001-06-08 | 2001-06-08 | 包含抗人精浆蛋白单链抗体/人羧肽酶a融合蛋白及前体药物的药盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2001/000924 WO2002100431A1 (fr) | 2001-06-08 | 2001-06-08 | Kit pharmaceutique comprenant une proteine de fusion carboxypeptidase humaine dirigee contre un anticorps a chaine simple de proteine plasmatique seminale et promedicament |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002100431A1 true WO2002100431A1 (fr) | 2002-12-19 |
Family
ID=4574810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2001/000924 WO2002100431A1 (fr) | 2001-06-08 | 2001-06-08 | Kit pharmaceutique comprenant une proteine de fusion carboxypeptidase humaine dirigee contre un anticorps a chaine simple de proteine plasmatique seminale et promedicament |
Country Status (4)
Country | Link |
---|---|
US (1) | US20050053611A1 (zh) |
EP (1) | EP1459761A4 (zh) |
CN (1) | CN1278739C (zh) |
WO (1) | WO2002100431A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103156884B (zh) * | 2012-04-28 | 2015-02-04 | 陕西精健新星生物医药有限公司 | 精浆的用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997007118A1 (en) * | 1995-08-18 | 1997-02-27 | William Alexander Denny | Enediyne compounds |
WO1998035982A1 (en) * | 1997-02-15 | 1998-08-20 | Zeneca Limited | Compounds for use in adept |
WO1998035988A1 (en) * | 1997-02-14 | 1998-08-20 | Zeneca Limited | Proteins |
WO1999039740A2 (en) * | 1998-02-03 | 1999-08-12 | Inex Pharmaceuticals Corporation | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206161A (en) * | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
US20030108544A1 (en) * | 1999-09-01 | 2003-06-12 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
US20020168737A1 (en) * | 2001-01-24 | 2002-11-14 | Cornish Virginia W. | Binding and catalysis screen for high throughput determination of protein function using chemical inducers of dimerization |
WO2002099040A2 (en) * | 2001-06-05 | 2002-12-12 | Exelixis, Inc. | Igs as modifiers of the p53 pathway and methods of use |
EP1560593B1 (en) * | 2002-10-25 | 2016-04-20 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
-
2001
- 2001-06-08 CN CNB018233376A patent/CN1278739C/zh not_active Expired - Fee Related
- 2001-06-08 EP EP01969178A patent/EP1459761A4/en not_active Ceased
- 2001-06-08 US US10/479,888 patent/US20050053611A1/en not_active Abandoned
- 2001-06-08 WO PCT/CN2001/000924 patent/WO2002100431A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997007118A1 (en) * | 1995-08-18 | 1997-02-27 | William Alexander Denny | Enediyne compounds |
WO1998035988A1 (en) * | 1997-02-14 | 1998-08-20 | Zeneca Limited | Proteins |
WO1998035982A1 (en) * | 1997-02-15 | 1998-08-20 | Zeneca Limited | Compounds for use in adept |
WO1999039740A2 (en) * | 1998-02-03 | 1999-08-12 | Inex Pharmaceuticals Corporation | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
Non-Patent Citations (2)
Title |
---|
See also references of EP1459761A4 * |
SHI PUTAO: "The solid phase synthesis of methotrexate-alpha-peptides", ACTA PHARMACEUTICA SINICA, vol. 32, no. 2, 1997, pages 106 - 109, XP008034351 * |
Also Published As
Publication number | Publication date |
---|---|
EP1459761A1 (en) | 2004-09-22 |
EP1459761A4 (en) | 2005-04-13 |
US20050053611A1 (en) | 2005-03-10 |
CN1278739C (zh) | 2006-10-11 |
CN1535159A (zh) | 2004-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5861223B2 (ja) | プロタンパク質およびその使用方法 | |
JP2008535475A (ja) | Q3sparc欠失変異体及びその使用 | |
JP4988333B2 (ja) | 免疫毒素を用いる癌を処置するための方法 | |
US20150105541A1 (en) | Antibody-active agent conjugates and methods of use | |
JP2017137316A (ja) | クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法 | |
KR20170031251A (ko) | 플라젤린 조성물 및 용도 | |
ES2747727T3 (es) | Composiciones y métodos para el diagnóstico y tratamiento del cáncer | |
JP6243452B2 (ja) | アルブミン結合アルギニンデイミナーゼ融合たんぱく質を含有する医薬組成物 | |
JP2007525196A5 (zh) | ||
JP2001520206A (ja) | 上皮細胞標的化結合体としてのj鎖およびアナログ | |
US10370410B2 (en) | Cancer cell-targeting peptide and use thereof | |
ES2240167T3 (es) | Polipeptido con actividad fibrinolitica. | |
JP3469247B2 (ja) | 組換えリボヌクレアーゼタンパク質 | |
JPH06502617A (ja) | 異常増殖性疾患措置のための抗体接合体 | |
US6395875B1 (en) | Recombinant soluble adenovirus receptor | |
WO2002100431A1 (fr) | Kit pharmaceutique comprenant une proteine de fusion carboxypeptidase humaine dirigee contre un anticorps a chaine simple de proteine plasmatique seminale et promedicament | |
He et al. | Effects of recombinant human canstatin protein in the treatment of pancreatic cancer | |
CA2481399A1 (en) | Peptides and pharmaceutical compositions comprising said peptides for treating cancer | |
JP2016524459A (ja) | 診断および治療目的のための抗体−ウレアーゼコンジュゲートの使用 | |
CN104119444B (zh) | 抗肿瘤融合蛋白及其制备方法和用途 | |
JPS60185799A (ja) | ヒト癌壊死因子 | |
ES2323407T3 (es) | Nuevo antigeno tumoral util en el diagnostico y terapia del cancer de vejiga, ovario, pulmon y riñon. | |
US7071311B2 (en) | Antibodies having specificity for 2′-C-allyl nucleic acids | |
CN116789837B (zh) | 一种抗组织因子人源化抗体及制备的抗体偶联药物和应用 | |
CN102250252A (zh) | 胃泌素释放肽导向融合蛋白 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 018233376 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001969178 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10479888 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2001969178 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |